image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Essentra

December 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • ESNT
  • Price:
  • 229p
There’s a growing case for the shares to make a stirring recovery. After the completion of the Filters sale (on track for end January ‘23), Essentra will have zero net debt even after paying an expected 50p special dividend, equivalent to almost a quarter of the market cap. Even better, Components is the highest margin, highest growth business left in the stable and should trigger a re-rating. Essentra’s Q3 update shows  like-for-like sales in Components, its sole remaining business, up 10.9% or +4.7% adjusting for four extra days. Although a slowing from the previous quarter, the keynote is that this was against tough comparables (+28% in Q3 ‘21). In September it opened a new distribution centre in Poland serving Europe, which wil ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author